Endoscopic UltrasoundPub Date : 2026-03-01Epub Date: 2026-05-14DOI: 10.1097/eus.0000000000000181
Masaki Miyazawa, Masahiro Yanagi, Hajime Takatori
{"title":"Disappearance of a disconnected pancreatic duct after pancreatic duct decompression in a pediatric case of walled-off necrosis (with video).","authors":"Masaki Miyazawa, Masahiro Yanagi, Hajime Takatori","doi":"10.1097/eus.0000000000000181","DOIUrl":"10.1097/eus.0000000000000181","url":null,"abstract":"","PeriodicalId":11577,"journal":{"name":"Endoscopic Ultrasound","volume":"15 2","pages":"153-155"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endoscopic UltrasoundPub Date : 2026-03-01Epub Date: 2026-05-14DOI: 10.1097/eus.0000000000000199
Khyati Bidani, Vishali Moond, Prateek S Harne, Hassam Ali, Ruchir Paladiya, Babu P Mohan, Arkady Broder, Nirav Thosani, Douglas G Adler
{"title":"Efficacy and safety of EUS-guided radiofrequency ablation in pancreatic neuroendocrine tumors: A systematic review and meta-analysis.","authors":"Khyati Bidani, Vishali Moond, Prateek S Harne, Hassam Ali, Ruchir Paladiya, Babu P Mohan, Arkady Broder, Nirav Thosani, Douglas G Adler","doi":"10.1097/eus.0000000000000199","DOIUrl":"10.1097/eus.0000000000000199","url":null,"abstract":"<p><p>EUS-guided radiofrequency ablation (EUS-RFA) has gained recognition in the last decade as a preferred alternative method for pancreatic neuroendocrine tumors (PNETS) where surgical resection is contraindicated. However, clinical outcomes of EUS-RFA for PNETS have not been well studied due to variability in procedure techniques and lack of data from good-quality studies. In this meta-analysis, we aim to study the pooled clinical outcomes of EUS-RFA in patients with PNETS. We searched multiple electronic databases and conference proceedings from inception through Jan 2024. The clinical outcomes studied were pooled technical success, clinical success, and adverse events. We also performed a subgroup analysis based on the sample size of the studies. Standard meta-analysis methods were employed using the random-effects model, and heterogeneity was studied by <i>I</i> <sup>2</sup> statistics. We analyzed 11 studies, which included 7 prospective and 4 retrospective studies involving 345 patients (55.3% females with a mean age of 58.73 ± 3.01 years) having a mean tumor size of 13.87 ± 0.82 cm and a mean duration follow-up of 13.36 months. Technical was assessed on per session basis, defined by EUS-guided access to PNETs along with the completion of the planned ablation procedure. Clinical success was defined as symptom resolution in functional lesions or complete ablation/disappearance or absence of imaging (cross-sectional or EUS) enhancement in nonfunctional lesions upon follow-up. The pooled technical success rate of EUS-RFA for PNETS was 97.6% (confidence interval 93.3%-99.2%; <i>I</i> <sup>2</sup> = 0%), and the pooled clinical success rate was 88.2% (76.3%-94.6%; <i>I</i> <sup>2</sup> = 74%). The pooled overall adverse event rate associated with EUS-RFA for PNETS was 19.6% (15.3%-24.9%; <i>I</i> <sup>2</sup> = 0%). The pooled rates of pancreatitis, bleeding, perforation, infection, and abdominal pain associated per procedure were as follows: 9.1% (6.2%-13.2%; <i>I</i> <sup>2</sup> = 0%); 4.0% (1.9%-8.2%; <i>I</i> <sup>2</sup> = 0%); 2.3% (1.0%-5.4%; <i>I</i> <sup>2</sup> = 0%); 2.3% (1.0%-5.4%; <i>I</i> <sup>2</sup> = 0%) and 8.8% (5.4%-14.1%; <i>I</i> <sup>2</sup> = 0%), respectively. There were no reported deaths with EUS-RFA. Due to the presence of small sample-size studies, subgroup analysis based on patient sample size of number (<i>N</i>) >20 and (<i>N</i>) <20 was performed. The pooled clinical success rate for studies with <i>N</i> >20 was 90.6% (68.1%-97.7%), whereas for studies with <i>N</i> <20 was 83.0% (69.3%-91.4%). On meta-analysis of EUS-RFA for PNETS, the overall technical success was 97.6%, the clinical success rate was 88.2%, and the overall adverse events was 19.6%. A key finding of this study was the pooled pancreatitis rate of 9.1%. Future studies are warranted to study methods aimed at pretreatment prophylactic measures to prevent this significant adverse event.</p>","PeriodicalId":11577,"journal":{"name":"Endoscopic Ultrasound","volume":"15 2","pages":"98-104"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endoscopic UltrasoundPub Date : 2026-03-01Epub Date: 2026-05-26DOI: 10.1097/eus.0000000000000200
Christoph F Dietrich, Andreas Helfen, André Ignee, Kathleen Möller, Yi Dong, Fabian Knebel
{"title":"Comments and illustrations on the complementary use of contrast-enhanced (endoscopic) ultrasound in cardiac tumors.","authors":"Christoph F Dietrich, Andreas Helfen, André Ignee, Kathleen Möller, Yi Dong, Fabian Knebel","doi":"10.1097/eus.0000000000000200","DOIUrl":"10.1097/eus.0000000000000200","url":null,"abstract":"<p><p>Primary cardiac tumors are rare, accounting for less than 0.1% of all neoplasms, whereas secondary cardiac involvement is considerably more frequent, particularly in advanced oncological disease. Although imaging modalities such as echocardiography, cardiac magnetic resonance imaging, computed tomography, and positron emission tomography are routinely used for the diagnosis and characterization of cardiac masses, the role of contrast-enhanced ultrasound (CEUS) has not yet been systematically evaluated. CEUS enables real-time visualization of vascularity and perfusion and offers important advantages for distinguishing tumors from thrombi, characterizing benign and malignant lesions, and detecting embolic sequelae in distant organs. In this review, we summarize current knowledge on the epidemiology, pathology, and clinical presentation of cardiac tumors and provide an overview of imaging strategies with a particular focus on CEUS. We illustrate the application of CEUS in the assessment of benign tumors such as myxomas and papillary fibroelastomas, rare benign entities, malignant cardiac tumors including sarcomas and lymphomas, and secondary cardiac involvement due to metastatic disease. The diagnostic value of CEUS is highlighted through image and video examples, demonstrating its ability to delineate perfused versus non-perfused tissue and to differentiate tumor vascularity patterns. CEUS represents a promising and underutilized imaging technique in the evaluation of cardiac tumors. It complements established imaging modalities, provides unique pathophysiological insights, and has the potential to improve diagnostic accuracy and clinical decision-making in selected patients.</p>","PeriodicalId":11577,"journal":{"name":"Endoscopic Ultrasound","volume":"15 2","pages":"87-97"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endoscopic UltrasoundPub Date : 2026-03-01Epub Date: 2026-05-11DOI: 10.1097/eus.0000000000000195
Bogdan Miutescu, Adrian Burdan, Eyad Gadour, Antonio Facciorusso, Mohammed AlQahtani, Iulia Ratiu, Camelia Nica, Ana Maria Ghiuchici, Mirela Danila, Roxana Sirli, Alina Popescu
{"title":"EUS point shear-wave elastography: A novel approach for noninvasive liver fibrosis assessment.","authors":"Bogdan Miutescu, Adrian Burdan, Eyad Gadour, Antonio Facciorusso, Mohammed AlQahtani, Iulia Ratiu, Camelia Nica, Ana Maria Ghiuchici, Mirela Danila, Roxana Sirli, Alina Popescu","doi":"10.1097/eus.0000000000000195","DOIUrl":"10.1097/eus.0000000000000195","url":null,"abstract":"<p><strong>Background and objective: </strong>EUS point shear‑wave elastography (EUS‑pSWE) permits near‑field, intraluminal assessment of liver stiffness.We examined its concordance with vibration-controlled transient elastography (VCTE) and its diagnostic accuracy for advanced fibrosis (F ≥ 3) in an expanded mixed cohort.</p><p><strong>Methods: </strong>One hundred twenty adults (57% men; mean age: 61 ± 10 years; body mass index: 28.9 ± 4.0) undergoing routine endoscopic ultrasound were prospectively enrolled. VCTE stratified fibrosis as F0-1 (<7.0 kPa, <i>n</i> = 96), F2 (7-9.4 kPa, <i>n</i> = 11) and F3‑4 (≥9.5 kPa, <i>n</i> = 13). In all the patients, 10 EUS‑pSWE measurements were performed in each lobe, and the liver stiffness result was the median value of the 10 measurements. Correlation (Pearson's <i>r</i>), Bland-Altman agreement, and diagnostic indices for F ≥3 were calculated.</p><p><strong>Results: </strong>Median EUS‑pSWE increased with fibrosis (left lobe: 5.0 ± 0.9, 7.8 ± 1.0, 15.1 ± 3.4 kPa for F0-1, F2, F3-4; <i>P</i> < 0.001). EUS-pSWE correlated strongly with VCTE (<i>r</i> = 0.89, left; <i>r</i> = 0.88, right; <i>P</i> < 0.0001). AUROC for detecting F ≥3 reached 0.91 (95% confidence interval: 0.85-0.96) for the left and 0.89 (0.83-0.95) for the right lobe. A 10.2 kPa cutoff value for F3 afforded 85% sensitivity, 84% specificity, positive predictive value 72%, and negative predictive value 93%. EUS-pSWE provided lobe-independent stiffness estimates that tracked VCTE closely to recognize advanced fibrosis.</p><p><strong>Conclusions: </strong>Its high diagnostic accuracy across fibrosis stages and ability to integrate seamlessly into routine EUS make EUS-pSWE a valuable tool for comprehensive liver assessment.</p>","PeriodicalId":11577,"journal":{"name":"Endoscopic Ultrasound","volume":"15 2","pages":"119-125"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endoscopic UltrasoundPub Date : 2026-03-01Epub Date: 2026-05-28DOI: 10.1097/eus.0000000000000161
Kimi Bessho, Takeshi Ogura, Akitoshi Hakoda, Saori Ueno, Atsushi Okuda, Nobu Nishioka, Jun Matsuno, Nobuhiro Hattori, Junichi Nakamura, Takafumi Kanadani, Nga Nguyen Trong, Hiroki Nishikawa
{"title":"Time to endosonography-created route formation after EUS-guided hepaticojejunostomy for performing antegrade procedures.","authors":"Kimi Bessho, Takeshi Ogura, Akitoshi Hakoda, Saori Ueno, Atsushi Okuda, Nobu Nishioka, Jun Matsuno, Nobuhiro Hattori, Junichi Nakamura, Takafumi Kanadani, Nga Nguyen Trong, Hiroki Nishikawa","doi":"10.1097/eus.0000000000000161","DOIUrl":"10.1097/eus.0000000000000161","url":null,"abstract":"<p><strong>Background and objectives: </strong>The antegrade procedure can be safely performed via an endosonography-created route (ESCR). Among the various types of surgically altered anatomy, antegrade procedures are frequently attempted in patients with Roux-en-Y (RY) anastomosis. For patients with RY anastomosis, EUS-guided hepaticojejunostomy (EUS-HJS) can be performed. However, evidence of the technical feasibility and safety of EUS-HJS is still limited, and there is no evidence of the time required for definitive formation of the ESCR after EUS-HJS. In the present study, we evaluated the time to formation of the ESCR after EUS-HJS for safely performing antegrade procedures.</p><p><strong>Method: </strong>Patients in whom EUS-HJS was attempted were eligible for study enrollment. The primary outcome of the present study was to evaluate the time to ESCR creation after EUS-HJS. This time was measured from the day of EUS-HJS to HJS stent removal. The technical success rates of EUS-HJS, HJS stent removal, the trans-ESCR procedure, and adverse events were secondarily evaluated.</p><p><strong>Results: </strong>A total of 42 patients were enrolled in the present study. The median interval prior to EUS-HJS stent removal was 10 days (range, 7-19 days). ESCR formation was confirmed in all patients who underwent EUS-HJS stent removal (100%, 42/42). The technical success rate of the subsequent trans-ESCR procedure was 95.2% (40/42). ESCR broken was not observed during procedures.</p><p><strong>Conclusions: </strong>In conclusion, sufficient formation of the ESCR for performing antegrade procedures might occur within 10 days after EUS-HJS in patients with RY anastomosis.</p>","PeriodicalId":11577,"journal":{"name":"Endoscopic Ultrasound","volume":"15 2","pages":"105-109"},"PeriodicalIF":4.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148249980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}